Slim Hopes Ride on a Patent Expiry as Obesity Drug Market Heats Up

Pharma firms circle March 2026 as semaglutide patent set to lapse in India; patients await affordable ‘magic shot’

March 20, 2026, may not yet be a red-letter day in Indian pharma calendars, but for drugmakers eyeing the weight-loss gold rush, it might as well be. That’s when the patent for semaglutide, the molecule behind the blockbuster anti-obesity injection Wegovy, expires in India—unlocking a market that’s as fat as the nation’s waistlines.

Once the preserve of the ultra-rich and jet-setting Bollywood celebrities, semaglutide-based therapies are now trickling into more “common” dinner-table conversations. And with over 250 million Indians classified as overweight or obese, the race to manufacture affordable generics could transform the treatment landscape—and the balance sheets of India’s top pharma players.

From Whispers to Forwarded Fantasies

Not long ago, the idea of a pharmaceutical injection for weight loss was the stuff of whispered conversations—anecdotes shared discreetly at high-end salons, murmured in the VIP lounges of airports, or inferred from the vanishing waistlines of those who had recently returned from a trip abroad. Today, it circulates freely—albeit with a generous helping of emojis—across family WhatsApp groups and late-night group chats, lumped in with skin serums, miracle teas, and cryptocurrency tips.

The sudden democratization of this once-exclusive therapy owes much to the arrival of two blockbuster drugs—Wegovy, from Novo Nordisk, and Mounjaro (tirzepatide), from Eli Lilly—on Indian soil. Priced, as executives like to say with a diplomatic smile, “for the local market,” these injectable medications have transformed the conversation around obesity from clinical to casual, from specialist prescription to everyday aspiration.

Both drugs are part of a class known as GLP-1 receptor agonists, initially developed to regulate blood sugar in patients with type 2 diabetes. But somewhere between efficacy trials and celebrity endorsements, they found new life as tools for weight management—working by mimicking a gut hormone that dampens hunger and gently coaxes the body toward satiety.

To call this a pivot would be to understate the elegance of the maneuver. Companies like Novo Nordisk and Eli Lilly, which built their reputations in the high-stakes world of insulin and metabolic care, have deftly repositioned themselves at the forefront of a rapidly expanding anti-obesity frontier. Their injectable pens—sleek, discreet, vaguely futuristic—are as much a symbol of pharmaceutical ingenuity as they are of a shifting cultural mood: a growing willingness to medicalize not just illness, but desire.

What was once hush-hush has become, almost overnight, an open secret. And in India, where scale and aspiration intersect in unpredictable ways, it has become something else entirely: a market.

The Price of Transformation

In India, these “magic shots” currently come with an uncomfortable price tag—Rs 14,000 to Rs 26,000 per month, depending on dosage. As most patients pay out of pocket, access remains limited. In contrast, US prices for the same therapies hover between $1,000 and $1,800 a month—but insurance there often softens the blow.

That, however, could change once the generics arrive.

Industry sources say Sun Pharma, Cipla, Dr Reddy’s Laboratories, Zydus Lifesciences, Biocon and others are already lining up their clinical trials, eyeing a 2026–27 launch window. A generic version could slash therapy costs by 20% to 30%—if not more.

India’s anti-obesity drug market, currently pegged at Rs 650 crore, is expected to double within three years. A pharmaceutical executive described it as a “once-in-a-decade opportunity”—not just for revenue, but for therapeutic impact.

The Fine Print: Not a Cosmetic Quick-Fix

But not everyone’s clapping.

Dr Ambrish Mithal, chairman of endocrinology and diabetes at Max Healthcare, issued a cautionary note. “These are powerful therapies meant for those who need medical weight management—not casual, cosmetic fixes. They must be used under medical supervision. The risk of misuse is very real,” he said.

Doctors say the injections work best when combined with diet and exercise. “The shot alone isn’t a magic wand,” said one bariatric consultant, “but it’s a powerful tool in the right hands.”

Since the April launch of Mounjaro, prescription numbers have already doubled. With Wegovy hitting Indian shelves in June, experts predict a further surge—and a growing risk of over-the-counter misuse.

Essential Medicine or Luxury Treatment?

The World Health Organization is now weighing whether to include semaglutide and similar GLP-1 drugs on its Model List of Essential Medicines. If approved, it could clear the way for pooled procurement and national health program integration—particularly for low- and middle-income countries.

There’s precedent—and pressure. A 2024 study by Médecins Sans Frontières, published in JAMA Network Open, estimated that such therapies could be profitably manufactured for as little as $0.89 per month. But in reality, retail prices range from $40 to over $350, depending on the country.

The pricing disparity, experts argue, is less about production and more about monopoly.

The Next Front in the Obesity Drug Race

Even as current treatments reshape the conversation around obesity, pharmaceutical companies are advancing the next generation of therapies — drugs that combine multiple hormone targets, including GLP-1, GIP, and glucagon agonists, to enhance efficacy and durability.

Oral formulations and longer-acting injectables are under development, led by global heavyweights such as Eli Lilly, Amgen, Boehringer Ingelheim, andNovo Nordisk. These companies are making substantial investments in a market that is quickly evolving from niche to mainstream.

According to a recent report by Goldman Sachs, daily oral medications could account for up to 25 percent of the global anti-obesity market by 2030, potentially outpacing injectable treatments in terms of patient preference and accessibility.

In this global shift, India is emerging as a critical player. With a population exceeding 1.4 billion, a rising incidence of diabetes and obesity, and a maturing pharmaceutical infrastructure, the country is no longer viewed solely as a destination for affordable generics. Increasingly, it is seen as a market with strategic importance — both for innovation and scale.

What began as a targeted solution for metabolic disease has rapidly evolved into a high-stakes race — with billions in revenue, public health outcomes, and global access at stake.

The shot, quite literally, has been fired.

Get updates and read additional stories on the Health Orbit Fan Page.

For Guest posts, sponsored posts and other details, please click the ‘Contact Us’ page.